Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Mometasone · Asmanex, Asmanex Hfa

Small molecule · Agonist of glucocorticoid receptor (NR3C1) · developed by Organon Llc

Approved FDA
1 Registered trials

What is Mometasone?

Mometasone furoate is a corticosteroid with potent anti-inflammatory activity that binds the human glucocorticoid receptor, suppressing inflammatory cells and mediators. It is used in the maintenance treatment of asthma as prophylactic therapy. A metered-dose spray formulation of mometasone furoate is also studied in seasonal allergic rhinitis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Asmanex, Asmanex Hfa
Drug type
Small molecule
Targets
glucocorticoid receptor (NR3C1)
Mechanism
Agonist of glucocorticoid receptor (NR3C1)
Pathways
anti-inflammatory signaling (inhibition of mast cells, eosinophils, neutrophils,, inhibition of histamine, eicosanoids, leukotrienes and cytokines
Therapy area
Respiratory
Developer
Organon Llc
In trials of
AMRX
FDA status
Approved as Asmanex, Asmanex Hfa, NDA205641 · FDA label

✅ FDA-approved uses

From the indications section of the FDA label (version of Jul 7, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT02125253 Phase 3 Seasonal Allergic Rhinitis Completed AMRX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Seasonal Allergic Rhinitis

Other drugs acting on NR3C1

Beclomethasone Dipropionate FDA approved Budesonide FDA approved IDP-118 FDA approved Infacort FDA approved Methylprednisolone FDA approved Mifepristone FDA approved Mometasone Furoate FDA approved Relacorilant FDA approved Chronocort Phase 3 Exicorilant Phase 1/2 Miricorilant Phase 2 ORIC-101 Phase 1

Sources

Updated Oct 11, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.